#gpt-rosalind

Life-science AI is moving from literature help toward executable research workflows. OpenAI says GPT-Rosalind reached 27.5% on MedChemBench, 21.6% on GeneBench, and 63.2% on LabWorkBench.

OpenAI is moving frontier AI deeper into biodefense, not only biomedical discovery. The post says Rosalind Biodefense and GPT-Rosalind access will support selected U.S. government and allied public-health missions.

OpenAI put GPT-Rosalind into research preview for qualified life-science teams, pairing a domain model with a Codex plugin that connects to more than 50 tools and data sources. The strongest signal is not the branding: OpenAI says best-of-ten submissions ranked above the 95th percentile of human experts on one Dyno Therapeutics RNA prediction task.

OpenAI is moving model specialization into scientific work rather than generic chat. GPT-Rosalind is framed for protein reasoning, chemical reasoning, genomics, biochemistry and tool use, with access starting as a research preview for qualified customers including Amgen and Moderna.